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Purpose: Occlusion caused by myointimal hyperplasia appears to be the main reason of late 
failure of polytetrafluoroethylene (PTFE) arterial bypass grafts. Evidence exists that 
growth factors are involved in the genesis of myointimal hyperplasia. The aim of this study 
was to assess the release of platelet-derived growth factor (PDGF) and basic fibroblastic 
growth factor (bFGF) by PTFE arterial grafts. 
Methods: In 15 inbred Lewis rats a i cm long segment of PTFE was interposed atthe level 
of the abdominal aorta. In a control group of another 15 Lewis rats a vein graft was 
implanted at the level of the abdominal aorta. Animals were killed 4 weeks after 
implantation a d the tissue was studied in organ culture for release ofPDGF AA, PDGF 
BB, and bFGF. 
Results: PTFE grafts released a greater quantity of PDGF AA than did control vein grafts 
(28  - 4 ng/cm~/72 hr vs 7 • 2 ng/cm2/72 hr). Similarly, PTFE grafts released a greater 
quantity of bFGF than did arterial vein grafts (308 --. 22 ng]cm2172 hr vs 204 • 20 
ng/cm2/72 hr). 
Conclusions: We conclude that PTFE arterial grafts release a high quantity of growth 
factor, which could explain, in part, the occurrence of distal anastomotic myointimal 
hyperplasia. (J VASC SURG 1996;23:453-60.) 
The development of anastomotic myointimal 
hyperplasia (MH) is the major obstacle in bypass 
grafting to small arteries. The phenomenon has been 
noted in infrainguinal rtery bypass with any pros- 
thetic material and, to a much lesser degree, with 
autologous saphenous veinY 3 
Factors involved in the genesis of anastomotic 
MH include local anastomotic factors such as 
trauma, compliance mismatch between graft and 
artery, and abnormal f ow hemodynamics. 47 Prob- 
ably biologic events occurring during transit of 
blood through the synthetic graft may contribute 
to the formation of anastomotic MH and acceler- 
ated atherosclerosis often seen in the arterial tree 
below a synthetic graft. 8
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Growth factors, cytokines, and other chemicals 
induce and regulate numerous cell functions during 
the process of MH and atherogenesis. 9,1~ Basic 
fibroblastic growth factor (bFGF) and platelet- 
derived growth factor (PDGF) are two of the 
best-characterized mitogens for smooth muscle cells. 
Several reports have demonstrated increased expres- 
sion of PDGF in association with naturally occurring 
atherosclerosis, experimentally induced atherosclero- 
sis, and MH associated with failure of vascular 
gra~$.9A 1"16 
bFGF is a member of the heparin-binding mito- 
gens, characterized by their affinity for heparin and 
ability to stimulate both endothelial and smooth 
muscle cell proliferation. 172~ Thus PDGF and bFGF 
may stimulate smooth muscle cell proliferation and 
eventually lead to formation of anastomotic MH. 
The purpose of our study was to analyze the 
release of PDGF and bFGF by polytetrafluoroethyl- 
ene (PTFE) grafts once inserted in the arterial 
circulation. An increased release of growth factors 
could explain, at least in part, the occurrence of 
anastomotic MH in synthetic grafts. Arterial vein 
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grafts, in which anastomotic MH occurs much less 
frequently, were used as control grafts. 
MATERIAL AND METHODS 
Experimental design. In 15 male inbred Lewis 
rats (average weight, 250 gm) a 1 cm long segment 
of nonreinforced PTFE (30 ~m fibril length, 2 mm 
internal diameter, and 0.39 mm thick; W.L. Gore & 
Associates Inc., Flagstaff, Ariz.) was inserted in the 
arterial system, at the level of the abdominal aorta. 
Four weeks after surgery the animals were killed and 
the PTFE grafts removed. The aorta above and below 
the graft and a segment of supradiaphragmatic 
inferior vena cava were also removed. 
The control group consisted of 15 male inbred 
Lewis rats (average weight, 250 gm) in which a I cm 
long segment of inferior vena cava was inserted at the 
level of the abdominal orta. The segments of inferior 
vena cava were obtained from syngeneic Lewis rats 
(same genetic pattern). Similarly, 4 weeks after 
surgery the animals were killed and the arterial vein 
graft, the aorta above and below the graft, and a 
segment of similar dimensions of endogenous infe- 
rior vena cava were explanted. 
Animal care complied with the Principles of 
Laboratory Animal Care as formulated by the Na- 
tional Society for Medical Research and the Guide for 
the Care and Use of Laboratory Animals (US 
Department of Health and Human Science, National 
Institutes of Health publication 80.23, revised 
1985). 
Operative procedures. The animals were anes- 
thetized with intramuscular xylazine (3 mg/kg) and 
intramuscular ketamine (50 mg/kg) supplemented by
intraperitoneal ketamine for maintenance. Surgery 
was performed with the use of an operating micro- 
scope (Zeiss OPMI-7D; Carl Zeiss, Inc., Thorn- 
wood, N.Y.). 
In the PTFE group the abdomen was opened and 
the abdominal aorta identified, and both proximal 
and distal control was obtained. The PTFE graft was 
inserted with end-to-end anastomoses with 10-0 
monofilament nylon sutures (Ethicon; Somerville, 
N.J.). Concerning the vein graft group, a i cm long 
segment of supradiaphragmatic inferior vena cava 
was obtained from donor rats. The chest was opened 
and the supradiaphragmatic portion of the inferior 
vena cava was identified and excised. The vein was 
kept moist in Dulbecco modified eagle medium 
(DMEM) for approximately 20 minutes while the 
receiving rat was anesthetized and the abdominal 
aorta identified. The vein grafts were inserted with 
end-to-end anastomoses with 10-0 monofilament 
nylon sutures (Ethicon Inc.). Throughout each 
procedure, care was taken to avoid unnecessary 
damage of the vein tissue. Four weeks after surgery, 
the animals were anesthetized and the abdomen and 
chest were opened. The aorta above the graft, the 
grafts, and a 1 cm long segment of supradiaphrag- 
marie inferior vena cava were exposed and excised. 
Histologic examination. Grafts (n = 3) were 
perfusion fixed with an initial infusion of Hanks' 
balanced salt solution, followed by 10% formalde- 
hyde. Following standard procedures, the specimens 
were stained with hematoxylin and eosin. For scan- 
ning electron microscopy, specimens were fixed in 
2.5% glutaraldehyde made up in 0.1 mol/L cacodyl- 
ate buffer (pH 7.2), rinsed several times, and left 1 
hour in the same buffer. Next the specimens were 
fixed 1 hour in osmium 1%, dehydrated in ascending 
concentrations of ethanol (15% to 100%), critical 
point dried in CO2, mounted in specimen stubs, and 
sputter coated with gold-palladium according to 
standard technique. All specimens were examined in 
a scanning electron microscope (S 570; Hitachi Ltd., 
Tokyo) at the accelerating voltage of 15 kV. 
Organ culture. The PTFE grafts, arterial vein 
grafts, control veins, and aortic segments were 
opened longitudinally and rinsed thoroughly for 10 
minutes with DMEM supplemented with antibiotics 
(gentamycin, 200 ~g/ml; streptomycin, 100 ~g/ml, 
and penicillin 100 IU/ml). The specimens (n = 12) 
were placed in 48-well Costar tissue culture plates 
(Costar, Cambridge, Mass.) for organ culture. The 
tissue was incubated in 1 ml DMEM supplemented 
with antibiotics at pH 7.4. The tissue was incubated 
for 5 days at 37 ~ C in a 5% CO2 atmosphere. Aliquots 
of conditioned media were collected at 72 hours and 
centrifuged for 5 minutes at 15,000 rpm and the 
supernatant was stored at -80  ~ C for assay of 
mitogenic activity and assay of PDGF AA, PDGF 
BB, and bFGF release. 
Assay for mitogenic activity. The presence of 
mitogenic activity in conditioned medium suggests 
that the medium contain mitogens that could stimu- 
late smooth muscle cell proliferation and lead to 
formation of MH. 
Swiss 3T3 cells were plated in 96-well plates 
(Falcon Plastics) at a density of 4 • 104 cells/ml in 
200 ~1 DMEM supplemented with 0.1% fetal calf 
serum. Seventy-two-hour conditioned serum-free 
media from PTFE grafts, vein grafts, and aortic 
segments were added to Swiss 3T3 cells (20 ~1). 
Positive controls received an equivalen t volume of 
DMEM plus human recombinant bFGF (20 ng/ml) 
or human recombinant PDGF (50 ng/ml) (Genzyme 
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Co., Boston, Mass.); negative controls received only 
DMEM. Al~ter 2 days, tritiated thymidine (0.5 ~Ci 
per well plate) was added and the cultures were 
incubated for 18 hours and collected on Skatron 
Filters (Skatron Instruments, Sterling, Va.) for 
determination fradioactivity inan LKB scintillation 
counter (LKB Instruments, Inc., Gaithersburg, 
Md.). 
Analysis of reduction of  mitogenic activity by 
anti-PDGF and anti-bFGF antibody. Reduction of 
mitogenic activity by antibody to specific growth 
factor suggests that the mitogenic activity is due to 
that particular growth factor. Measurement of the 
Swiss 3T3 cells DNA synthesis-stimulating activity of 
the conditioned media from PTFE grafts was re- 
peated in the presence of an excess of monospecific 
antibody to human PDGF (50 ixg/ml) (Genzyme 
Co.) and an excess of monoclonal ntibody to human 
bFGF (produced in our laboratory), which cross- 
react with rat growth factor. Tritiated thymidine was 
again added and the cultures were incubated for 18 
hours. After further processing, the radioactivity was 
measured. 
Assay of PDGF AA, PDGF BB, and bFGF in 
the conditioned media. The presence of bFGF, 
PDGF AA, and PDGF BB molecules in the serum- 
free conditioned media from vein grafts, PTFE 
grafts, control veins, and aortic segments were 
determined by inhibition antibody-binding assay. A 
dilution of anti-bFGF mouse monoclonal antibody 
that showed 50% maximal reactivity against bFGF (4 
ixg/ml) was incubated with various dilutions of 
conditioned media in 400 ~1 tubes precoated with 
phosphate-buffered saline (PBS) gelatin 2%. After 20 
hours of incubation at 4 ~ C, Staphylococcus aureus 
protein A was added, and the immunoaggregates 
were removed by centrifugation. The residual 
antibody-binding activity in the supernatant was 
measured by enzyme-linked immunosorbent assay 
(ELISA). Plastic wells (96 wells; Falcon Plastics) 
were coated with bFGF (10 ng per well) for 8 hours 
at 4 ~ C. Plates were then washed twice with PBS and 
saturated with PBS-gelatin 1% for 2 hours at 37 ~ C. 
Washed wells were then filled with 50 I~1 per well 
supernatant obtained after immunoprecipitation. Af- 
ter 2 hours of incubation at 37 ~ C, the wells were 
washed with PBS-gelatin 0.1%. Peroxidase-labeled 
goat antimouse immunoglobulin antibody was 
added. After 60 minutes of incubation at 37 ~ C, the 
plate was washed three times in PBS-gelatin 0.1% 
and once in distilled water. Finally, O-phenylene- 
diamine dihydrochloride (0.4 mg/ml) (Sigma 
Chemical Co., St. Louis, Mo.) was added as substrate 
for the enzyme. Bound specific antibody was mea- 
sured quantitatively b  optical density reading at 492 
nm with a spectrophotometer (Beckman Instru- 
ments, Inc., Palo Alto, Calif.). The amount of bFGF 
in the conditioned media was determined by usc of a 
reference curve obtained with known quantities of 
human recombinant bFGF. We used mouse anti- 
bFGF monoclonal antibody as positive control and 
antibody without specificity as negative control. 
Similar experiments were used to determine the 
prcscnce and amount ofPDGF AA and PDGF BB in 
the conditioned media, with rabbit polyclonal anti- 
body to PDGF AA and rabbit polyclonal antibody to 
PDGF BB, respectively. 
Statistical analysis. Statistical analysis was per- 
formed with Statview software (Abacus Concepts, 
Inc., Berkeley, Calif.) on a Macintosh Powerbook 
microcomputer (Apple Computer, Inc., Cupertino, 
Calif.). Data were expressed as mean _+ SD. Differ- 
ences bctween the groups were analyzed by use of the 
two-tailed Student  test and analysis of variance. 
RESULTS 
All grafts were patent at the time of death. 
Histology. At harvest, PTFE grafts (n = 3 fbr 
each group) showed evidence of a minor degree of 
MH at the level of the anastomosis. Endothelial cells 
recognizable for their cobblestone appearance x- 
tended from the adjacent artery across the anastomo- 
sis and into the graft for only a few millimeters (Fig. 
1). The midgraft region was covered bv thrombus 
and fibrin. Few platelets and leukocytes were present 
in the midportion of the PTFE grafts (a mean of fbur 
for each field examined). The tissue surrounding the 
PTFE graft penetrated the interstices of the graft. 
Rare tufts of ingrowth tissue arrived to the lumenal 
surface. Vein grafts were completely covered by 
endothelial cells as recognized by their cobblestone 
appearance. Few scattered platelets and leukocytes 
were present in the lumen (a mean of four fbr each 
field examined). 
Mitogenic activity of the conditioned media. 
Addition of serum-free conditioned media f?om 
PTFE grafts collected at 72 hours (n = 12 for each 
group) produced astatistically significant increase of 
tritiated thymidine uptake of Swiss 3T3 cell cultures 
compared with conditioned media from vein grafts. 
Fig. 2 shows the mitogenic activity of conditioned 
media from PTFE grafts, vein grafts, and thoracic 
aorta. These differences were statistically significant 
(p < 0.01), and the higher quantity of mitogens 
released could stimulate the growth of smooth 
muscle cells and lead to formation of MH. 
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Fig. 1. Scanning electron microphotograph of distal anastomotic region of PTFE graft 
implanted for 4 weeks in abdominal aorta of rat. Endothelial ce ls extended from adjacent artery 
across anastomosis and into graft only for few millimeters. (Original magnification x 180.) 
Reduction of  mitogenic activity by anti-bFGF 
and anti-PDGF antibody. Reduction of mitogenic 
activity by anti-bFGF and anti-PDGF antibodies 
(n -- 12 for each group) means that the mitogenic 
activity is due to that particular growth factor. 
Addition of monospecific anti-bFGF antibody to the 
medium of 3T3 cell cultures exposed to conditioned 
medium from PTFE grafts decreased the uptake of 
tritiated thymidine by 65% (p < 0.001) (Fig. 3). 
Addition ofmonospecilic anti-PDGF antibody to the 
medium of 3T3 cell cultures exposed to conditioned 
medium from PTFE grafts decreased the uptake of 
tritiated thymidine by 20% (p < 0.05) (Fig. 4). 
PDGF assay by ELISA. Tables I and II show the 
release of PDGF AA and PDGF BB from control 
veins, arterial vein grafts, aortic segments, and PTFE 
grafts (n = 12 for each group). The release of PDGF 
BB was similar in arterial vein grafts and PTFE grafts. 
Release ofPDGF AA was statistically higher in PTFE 
grafts (p < 0.05). 
bFGF assay by ELISA. Table III shows the 
release of bFGF by control veins, arterial vein grafts, 
aortic segments, and PTFE grafts (n = 12 for each 
group). The release of bFGF was statistically higher 
in arterial vein grafts and PTFE grafts than in aortic 
segments (p < 0.01). PTFE grafts released a signifi- 
can@ higher amount of bFGF than did arterial vein 
grafts (p < 0.05). 
DISCUSSION 
Anastomotic MH is more common in cases of 
synthetic grafts and at the level of the distal 
anastomosis. ~3Many theories have been proposed 
regarding the biogenesis and cause of this pathologic 
entity. Local anastomotic factors probably play a 
major role. Bassiouny et al. 6 found anastomotic MH 
JOURNAL OF VASCULAR SURGERY 
Volume 23, Number 3 Str et al. 457 
u,l 
l - -  
~J 
Z 
~5ooo 
I,,,, 
5O00 
z 
> 
o 
T 
T 
i!iiiiiiiii!i~i!iiiii! 
::i:ili::ii:i;i:::ill 
:;:iiiiii!:ii!i!i!:!i; : .: .  : : . . :  
ili!iiiiiiiii!!i!i 
ii;~iliiii~i!!~i 
: : . :  : : : . : .  
i+iii!i~iiii!iiii : : : : : : . :  : : . : : : , : . : :  
Fig. 2. Addition of serum-free conditioned media from PTFE grafts collected at 72 hours 
produced significant increase of tritiated thymidine uptake of Swiss 3T3 cell cultures compared 
with conditioned media from vein grafts and conditioned media from thoracic aorta. All these 
differences were statistically significant (n = 12 for each group) (DMEM: negative control; 
human recombinant PDGF and bFGF: positive controls). 
in two zones: suture fine, which represents a conse- 
quence of  vascular healing, and arterial floor, which 
develops in a region of flow oscillation and relatively 
low shear. In either situation the response was 
associated with altered flow conditions. Abbott et al.s 
attributed compliance mismatch between the graft 
and the host artery as being the cause of  anastomotic 
MH. Ojha et al. 21 demonstrated greater flow distur- 
bances at this level. They found low wall shear stress 
at the level of the toe and heel of  the anastomosis and 
high shear stress on the bed. How these different 
factors may lead to MH is ill defined. 
Several studies have shown that abnormal hemo- 
dynamic conditions may lead to an increased release 
of  bFGF and PDGF by endothelial and smooth 
muscle cells. 2z'24 Many other studies have shown a 
correlation between PDGF and bFGF and MH. 
Jawien et al. 2s found that PDGF infused into rats 
subjected to balloon carotid artery injury produced a 
twofold to threefold increase in medial smooth 
muscle cell proliferation, and a twentyfold increase in 
migration of  smooth muscle cells from the media to 
the intima during the first 7 days. In a similar 
experimental model, administration of antibodies to 
PDGF resulted in a 40% reduction in area of MH. z6 
A similar role has been attributed to bFGF. Lindner 
and Reidy 27 have shown that proliferation of smooth 
muscle cells was reduced significantly in animals that 
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Fig. 3. Addition ofmonospecific anti-PDGF antibody to 
medium of 3T3 cell cultures exposed to conditioned 
medium from PTFE grafts implanted 4 weeks in rat 
abdominal orta decreased uptake of tritiated thymidine by 
20% (empty column), (n = 12 for each group) (DMEM: 
negative control; PDGF: positive control). 
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Fig. 4. Addition of monospecific anti-bFGF antibody to 
medium of 3T3 cell cultures exposed to conditioned 
medium from PTFE grafts implanted 4 weeks in rat 
abdominal orta decreased uptake of tritiated thymidine by 
65% (empty column) (n = 12 for each group) (DMEM: 
negative control; bFGF: positive control). 
received anti-bFGF antibodies before balloon angio- 
plasty. Thus many studies support a role for bFGF 
and PDGF in the genesis of MH. It is possible that 
the graft itself generates a substance that could 
Table I. Release of PDGF BB 
Graft PDGF BB (ng/cm2/72 hr) 
Control vein 4 -+ 2 
Arterial vein 62 +- 6 
PTFE 66 -+ 7 
Thoracic aorta 25 -+ 4 
Each value represents he mean +_ SD of 12 separate xperiments. 
Table II. Release of PDGF AA 
Graft PDGF AA (ng/cm2/72 hr) 
Control vein 7 _+ 3 
Arterial vein 7 +- 2 
F IFE  28 -+ 4 
Thoracic aorta 7 -+ 4 
Each value represents he mean +_ SD of 12 separate xperiments. 
Table II I .  Release of bFGF 
Graft bFGF (ng/cm2/72 hr) 
Control vein 55 -+ 6 
Arterial vein 295 -+ 20 
PTFE 404 - 22 
Thoracic aorta 46 +- 8 
Each value represents he mean _+ SD of 12 separate xperiments. 
contribute to distal anastomotic MH. In our study we 
found that PTFE grafts release growth factors. The 
release of PDGF AA and especially bFGF was much 
higher than in arterial vein grafts. Zacharias et al.28 
reported that perfusates from PTFE grafts implanted 
in baboons contained more mitogenic activity than 
perfusates from arteries. Experimental studies from 
the same laboratory 29 showed that the intima of 
PTFE grafts implanted in baboons expressed higher 
levels of PDGF A mRNA than the native aorta. 
Kaufman et al. 3~ analyzed the production of PDGF 
by PTFE grafts seeded with autologous endothelial 
cells and implanted in dogs. PDGF production 
increased with time and was greater in the distal 
portion of the graft. Interestingly, PDGF production 
increased with time also in the control, unseeded 
PTFE graft group. Again, PDGF production was 
greater at the level of the distal anastomosis where 
intimal thickness was more evident. In our study we 
confirmed the increased release of PDGF. However, 
the most striking difference between PTFE and vein 
grafts was the amount of bFGF released by synthetic 
grafts. The source ofbFGF and PDGF is speculative. 
Platelets, leukocytes, endothelial cells, smooth 
muscle cells, and macrophages are able to release 
PDGF and bFGF. Platelet survival is shortened after 
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graft implantation and platelet deposition on pros- 
thetic grafts is well documented, s~ 
Endothelial cells migrate from the adjacent artery 
onto the graft. This is a slow process limited to a few 
millimeters from the anastomosis. In vitro studies 
suggest hat endothelial cells in culture are activated 
and produce a higher quantity of PDGFY Similarly, 
endothelial cells migrating onto a synthetic graft may 
activate and release a greater quantity of growth 
factors. Smooth muscle cells proliferate underneath 
endothelial cells and, similarly, could be the source of 
growth factors. Ingrowth of capillaries through graft 
interstices is a well-known phenomenon in high- 
porosity (60 to 90 Ixm) PTFE, especially in ba- 
boons.SS,S4 We found ingrowth of capillaries through 
the graft, even if very few reached the lumen. This 
ingrowth of tissue might contribute to growth factor 
release. Leukocyte and macrophage infiltration char- 
acterizes the chronic inflammatory response to vas- 
cular prostheses. 
Organ culture was used in our study. This 
technique has many advantages, including mainte- 
nance of the normal tissue structure in anatomic and 
functional terms. The shortcomings of the technique 
are that it does not allow identification of the cells 
responsible for the production of growth factors and 
does not exclude the contribution from cells residing 
outside the graft. 
In our study we have found that PTFE grafts 
release a greater quantity of growth factors than do 
arterial vein grafts. This phenomenon could contrib- 
ute to the development of distal anastomotic MH and 
the progression ofatherosclerosis in the distal arterial 
tree that is often seen when synthetic grafts are im- 
planted. 
Agents able to reduce the release of these growth 
factors may contribute to the prevention of anasto- 
motic MH. 3s 
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